Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Is breastfeeding after breast cancer safe and feasible?

Eva Blondeaux • 14 Sep 2024
ESMO 2024
Breast Cancer

Eva Blondeaux, MD, University of Genova, Genova, Italy, shares findings from a trial (NCT03673306), which included 4,732 women with breast cancer, 659 of whom became pregnant post-diagnosis. Of these, 474 had live births, with 23.2% opting to breastfeed. The median breastfeeding duration was five months, and the study found no increased risk of cancer recurrence among women who breastfed compared to those who did not. This study is the first to demonstrate that breastfeeding after breast cancer is both safe and feasible for survivors. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eva Blondeaux

Risk-reducing surgeries and survival in young BRCA carriers with breast cancer
4:04
Risk-reducing surgeries and survival in young BRCA carriers with breast cancer
Eva Blondeaux • 9 May 2025
Evaluating breastfeeding feasibility after breast cancer in BRCA carriers
0:56
Evaluating breastfeeding feasibility after breast cancer in BRCA carriers
Eva Blondeaux • 14 Sep 2024
Lifestyle and pregnancy factors impacting breastfeeding in breast cancer survivors
0:44
Lifestyle and pregnancy factors impacting breastfeeding in breast cancer survivors
Eva Blondeaux • 14 Sep 2024
Counseling breast cancer survivors on breastfeeding
0:47
Counseling breast cancer survivors on breastfeeding
Eva Blondeaux • 14 Sep 2024

Related Videos

Stress and depression linked to tumor transcriptional signatures in breast cancer
1:21
Stress and depression linked to tumor transcriptional signatures in breast cancer
Shipra Gandhi • 31 May 2026
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
1:13
DESTINY-Breast07: final analysis of T-DXd and durvalumab in 1L HER2+ breast cancer
Shipra Gandhi • 31 May 2026
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
1:34
TBCRC-053: preoperative radiotherapy & pembrolizumab in node-positive TNBC
Shipra Gandhi • 1 Jun 2026
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
0:49
HELEN-Trio 011: camrelizumab plus chemotherapy as neoadjuvant therapy in TNBC
Shipra Gandhi • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals